Terms: = Brain cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Staging
5 results:
1. The "Great Debate" at Melanoma Bridge 2021, December 2nd-4th, 2021.
Ascierto PA; Warner AB; Blank C; Caracò C; Demaria S; Gershenwald JE; Khushalani NI; Long GV; Luke JJ; Mehnert JM; Robert C; Rutkowski P; Tawbi HA; Osman I; Puzanov I
J Transl Med; 2022 May; 20(1):200. PubMed ID: 35538491
[TBL] [Abstract] [Full Text] [Related]
2. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract] [Full Text] [Related]
3. [Small-cell lung cancer: epidemiology, diagnostics and therapy].
Pešek M; Mužík J
Vnitr Lek; 2018; 63(11):876-883. PubMed ID: 29303289
[TBL] [Abstract] [Full Text] [Related]
4. New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing ctla4 monoclonal antibody treatment.
Murphy KP; Kennedy MP; Barry JE; O'Regan KN; Power DG
Oncol Res Treat; 2014; 37(6):351-3. PubMed ID: 24903767
[TBL] [Abstract] [Full Text] [Related]
5. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients.
Rinne D; Baum RP; Hör G; Kaufmann R
Cancer; 1998 May; 82(9):1664-71. PubMed ID: 9576286
[TBL] [Abstract] [Full Text] [Related]
